Oops. Pfiz­er's CDK 4/6 block­buster Ibrance flunks the OS mark for breast can­cer

Just weeks af­ter No­var­tis $NVS set out to bur­nish its prospects in breast can­cer with promis­ing pro­gres­sive-free sur­vival num­bers for Kisqali and ful­ves­trant in treat­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER